Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
Semaglutide is a long-acting GLP-1 receptor agonist. It increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite, so ProtoComp uses it to lower appetite expectations, monitor nausea risk, and protect protein intake during training phases.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The New England journal of medicine · 2021 · PMID 33567185
FDA-approved GLP-1 RA. Wegovy (obesity): titrate to 2.4 mg weekly. Ozempic (T2D): 0.5-2 mg weekly. Start at 0.25 mg weekly and titrate every 4 weeks.
No published cycle data available.
Consistent day of week. Food timing does not affect absorption.
Contraindications
- • Personal or family history of medullary thyroid carcinoma (MTC)
- • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- • History of pancreatitis
- • Severe gastroparesis
Common side effects
- • Nausea
- • Vomiting
- • Diarrhea
- • Constipation
- • Appetite suppression
- • Fatigue
Serious risks
- • Acute pancreatitis
- • Gallbladder disease
- • Kidney injury from dehydration
- • Gastroparesis
- • Thyroid C-cell tumors (boxed warning)
Drug interactions
- • Delays gastric emptying — may slow absorption of oral medications
- • Insulin/sulfonylureas (hypoglycemia risk)
Requires monitoring
- • HbA1c
- • Weight
- • Kidney function
- • Pancreatic enzymes if symptomatic
Pregnancy / breastfeeding
Contraindicated — discontinue 2 months before planned pregnancy
- Not a shortcut — GI side effects are common and rebound weight gain is documented after discontinuation
- Muscle loss occurs alongside fat loss without adequate protein and resistance training
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.